Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

75 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-11-30

Study Completion Date

2014-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Placebo-controlled, double blind (triple-dummy technique), randomised parallel design comparison of three oral doses (2.5 mg, 10 mg, and 25 mg) of empagliflozin in patients with T1DM as adjunctive therapy to insulin over 28 days. Patients will undergo a 14-day open-label placebo run-in period before randomisation. Background insulin therapy will be kept stable during the first 7 days of the treatment period and will be freely adjusted thereafter.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)

NCT02414958

Diabetes Mellitus, Type 1

COMPLETED PHASE3

Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)

NCT02580591

Diabetes Mellitus, Type 1

COMPLETED PHASE3

Empa Add on to Insulin in Japanese Patient With Type 1 Diabetes Mellitus

NCT02702011

Diabetes Mellitus, Type 1

COMPLETED PHASE2

Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)

NCT00641056

Type 2 Diabetes Mellitus

COMPLETED PHASE3

A Study of a New Type of Insulin in Participants With Type 1 Diabetes on Insulin Injection Therapy

NCT02623452

Diabetes Mellitus, Type 1

WITHDRAWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 1

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Empagliflozin low

Empagliflozin low once daily

Group Type EXPERIMENTAL

Empagliflozin medium placebo

Intervention Type DRUG

Empagliflozin medium placebo

Empagliflozin high placebo

Intervention Type DRUG

Empagliflozin high placebo

Empagliflozin low

Intervention Type DRUG

Empagliflozin low

Empagliflozin medium

Empagliflozin medium once daily

Group Type EXPERIMENTAL

Empagliflozin low placebo

Intervention Type DRUG

Empagliflozin low placebo

Empagliflozin high placebo

Intervention Type DRUG

Empagliflozin high placebo

Empagliflozin medium

Intervention Type DRUG

Empagliflozin medium

Empagliflozin high

Empagliflozin high once daily

Group Type EXPERIMENTAL

Empagliflozin medium placebo

Intervention Type DRUG

Empagliflozin medium placebo

Empagliflozin low placebo

Intervention Type DRUG

Empagliflozin low placebo

Empagliflozin high

Intervention Type DRUG

Empagliflozin high

Placebo

Placebo once daily

Group Type PLACEBO_COMPARATOR

Empagliflozin low placebo

Intervention Type DRUG

Empagliflozin low placebo

Empagliflozin high placebo

Intervention Type DRUG

Empagliflozin high placebo

Empagliflozin medium placebo

Intervention Type DRUG

Empagliflozin medium placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Empagliflozin medium placebo

Intervention Type DRUG

Empagliflozin low placebo

Intervention Type DRUG

Empagliflozin low placebo

Intervention Type DRUG

Empagliflozin high placebo

Intervention Type DRUG

Empagliflozin medium

Intervention Type DRUG

Empagliflozin medium placebo

Intervention Type DRUG

Empagliflozin high placebo

Intervention Type DRUG

Empagliflozin high placebo

Intervention Type DRUG

Empagliflozin medium placebo

Intervention Type DRUG

Empagliflozin low placebo

Intervention Type DRUG

Empagliflozin low

Intervention Type DRUG

Empagliflozin high

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed and dated written informed consent
* Male or female patient receiving insulin for treatment of T1DM for at least 12 months
* C-peptide \< 1.5 ng/mL
* Age 18 to 65 years
* HbA1c of 7.5% to 10.5%
* Multiple daily injections (MDI) of any type of insulin
* Willing to follow an established and individualized carbohydrate counting method and an insulin administration algorithm
* Body Mass Index of 18.5 to 35.0 kg/m2
* Estimated glomerular filtration rate 60 to 150 mL/min/1.73 m²
* Able and willing to perform study assessments according to investigator's judgement
* Compliance with trial drug administration 80% to 120% during run-in period
* Willing not to take any paracetamol containing drugs during the trial

Exclusion Criteria

* Acute symptomatic urinary tract infection or genital infection, chronic or recurrent cystitis
* History of type 2 diabetes mellitus, maturity onset diabetes of the young (MODY), pancreatic surgery or chronic pancreatitis
* Pancreas, pancreatic islet cells or renal transplant recipient
* Type 1 diabetes mellitus treatment with any other antihyperglycaemic drug except insulin within last 3 months or history of clinically relevant hypersensitivity
* Occurrence of hypoglycaemia that required hospitalization or treatment by an emergency physician or paramedic within last 3 months
* Hypoglycaemia unawareness or frequent episodes of unexplained hypoglycaemia
* Occurrence of diabetic ketoacidosis that required hospitalization or treatment by an emergency physician or paramedic within last 12 months
* History of macrovascular disease including cardiovascular, cerebrovascular and peripheral artery disease
* Autonomic neuropathy with gastroparesis
* Brittle diabetes
* Liver disease
* Treatment with anti-obesity drugs, surgery or aggressive diet regimen leading to unstable body weight
* Treatment with systemic corticosteroids
* Change in dose of thyroid hormones within last 6 weeks or planned change or initiation of such a therapy
* Medical history of cancer or treatment for cancer in the last five years
* Blood dyscrasias or any disorders causing haemolysis or unstable red blood cells
* Alcohol or drug abuse that would interfere with trial participation or any ongoing clinical condition that would jeopardize patient's or site personnel's safety or study compliance
* Intake of an investigational drug in another trial within last 30 days
* Not able to understand and comply with study requirements
* Pre-menopausal women who are nursing or pregnant or of child-bearing potential and are not practising an acceptable method of birth control

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No